Researchers

KUDO Masatoshi

KUDO Masatoshi: Professor/Senior Staff

Faculty	Department of Medicine / Graduate School of Medical Sciences
Researchmap	https://researchmap.jp/m-kudo

Education and Career

Academic & Professional Experience

Apr. 1999 - Today , Kindai University Faculty of Medicine Professor and Chairman

Research Activities

Research Areas

Life sciences, Medical systems
Life sciences, Gastroenterology
Life sciences, Tumor diagnostics and therapeutics

Research Interests

Hepatocellular carcinoma, 肝腫瘍の画像診断, Conrast-ehnaced ultrasonogaraphy, EOB-MRI, Radiofreuqency ablation (RFA), Transarterial chemoembolization (TACE), 肝動注化学療法, Molecular targeted therapy, 血管新生阻害治療, Immunotherapy, Immune checkpoint inhibitor

Published Papers

Genetic/epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: Transforming the immune microenvironment with molecular targeted agents
Naoshi Nishida; Masatoshi Kudo
Liver Cancer (in press) , 1-14, Dec. 2023 , Refereed
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Valentina Burgio; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita Rimini
International journal of cancer 23, Nov. 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.
Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Keisuke Yokohama; Hiroki Nishikawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Atsushi Naganuma; Yutaka Yata; Hideko Ohama; Hidekatsu Kuroda; Kazunari Tanaka; Takaaki Tanaka; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada
Cancer medicine 21, Nov. 2023

アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療 , 小川力; 福家和諭; 真鍋卓嗣; 柴峠光成; 工藤正俊 , Wnt/βカテニン変異の症例に対するアテゾリズマブ・ベバシズマブ併用療法の使用経験 , Wnt/βカテニン変異の症例に対するアテゾリズマブ・ベバシズマブ併用療法の使用経験 , アークメディア , Sep. 2021
アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療 , 工藤正俊 , アテゾリズマブ・ベバシズマブ併用療法の登場による肝細胞癌治療の今後の展開 , アテゾリズマブ・ベバシズマブ併用療法の登場による肝細胞癌治療の今後の展開 , アークメディア , Sep. 2021
アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療 , 青木智子; 上嶋一臣; 工藤正俊 , アテゾリズマブ・ベバシズマブ併用療法のpatient reported outcomes , アテゾリズマブ・ベバシズマブ併用療法のpatient reported outcomes , アークメディア , Sep. 2021

切除不能HCCに対するABC conversion療法とclinical CRの現状. ワークショップ「肝がん局所治療の多様性とその到達点」 , 青木智子; 西田直生志; 工藤正俊 , 第45回日本肝臓学会西部会 , 7, Dec. 2023
SIERRA: A Phase 3b, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma , Chan SL; Sangro B; Kudo M; Dane A; Emery C; Paskow MJ; Makowsky M; Nguyen B; Rimassa L , ESMO-Asia 2023 , 1, Dec. 2023
IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC) , Yamashita T; Inaba Y; Ikeda M; Sone M; Yamakado K; Nioshiofuku H; Tsuchiya K; Tada T; Sato Y; Kodama T; Kuzuya T; Ogasawara S; Ueno M; Iwamoto H; Moriguchi M; Ueshima K; Kodama Y; Takehara T; Hamano T; Kudo M , ESMO-Asia 2023 , 1, Dec. 2023

【薬物療法によって変貌する肝細胞癌治療:2023 Update】肝細胞癌に対する薬物療法京都コンセンサス2023 , 工藤正俊; Llovet Josep M.; Finn Richard S. , 肝胆膵 , 87 , 4 , 369 , 379 , Oct. 2023
【薬物療法によって変貌する肝細胞癌治療:2023 Update】Early stage肝細胞癌肝細胞癌での腫瘍免疫微小環境とアジュバント療法における免疫チェックポイント阻害剤の役割 , 西田直生志; 工藤正俊 , 肝胆膵 , 87 , 4 , 381 , 387 , Oct. 2023
【薬物療法によって変貌する肝細胞癌治療:2023 Update】Intermediate-stage肝細胞癌 ABC conversion療法その効果と適応 , 工藤正俊 , 肝胆膵 , 87 , 4 , 425 , 437 , Oct. 2023